[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"kidney-injury\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:kidney-injury":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,45,77,111,174,199,232,268,295,323,347,373,395,415,439],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100613090","phase-2-improving-preterm-kidney-outcomes-with-caffeine-100613090",false,"NCT07262060","Improving Preterm Kidney Outcomes With Caffeine","Optimizing Caffeine Therapy for Hypoxia in Preterm Neonates: A Randomized Trial Assessing Efficacy, Acute Kidney and Brain Injury, Safety, and Pharmacokinetics","Inclusion Criteria:\n\n* Gestational age at birth between 23 0\u002F7 and 29 6\u002F7 weeks.\n* Able to have near-infrared spectroscopy (NIRS) monitoring of cerebral and kidney oxygenation.\n* Able to receive IV medications.\n* Indwelling umbilical arterial catheter (UAC), umbilical venous catheter (UVC), peripheral arterial line (PAL), or peripherally inserted central catheter (PICC) already in place that can draw blood.\n* Receiving caffeine at the time of enrollment\n* Have a birth parent who is at least 18 years old and have a parent or guardian who is able to provide parental permission in English or Spanish\n\nExclusion Criteria:\n\n* Known or suspected major congenital anomaly of the brain, heart, lungs or kidney (excluding UTD A1 pyelectasis).\n* Known or suspected chromosomal or genetic anomaly.\n* Not suitable for study participation due to other reasons at the discretion of the investigators.","ALL","12 Hours","96 Hours",{"count":20,"type":21},114,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study is being done to see if additional caffeine citrate (20 milligrams per kilogram IV bolus) helps babies with low kidney oxygenation already being treated with caffeine citrate (20 milligrams per kilogram IV bolus on day of life (DOL) 1 followed by 8 milligrams per kilogram daily maintenance). The investigators hypothesize that additional caffeine will improve kidney oxygen levels, while not causing any brain injury, and may reduce rates of acute kidney injury compared to placebo. This study will take place in preterm babies born less than 30 weeks gestational age, with the intervention occurring between greater than 48 hours of age until DOL 14 and outcomes tracked until neonatal intensive care unit (NICU) discharge.",[27,28],"Kidney Injury","Pre-Term",[30,31],"caffeine","acute kidney injury","RECRUITING","2026-06-02",{"date":35,"type":36},"2026-06-04","ACTUAL",{"date":38,"type":36},"2026-05-28",{"date":40,"type":21},"2030-09",{"name":42,"class":43},"University of Wisconsin, Madison","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":44},"100634690","transgender-analysis-of-nephrological-studies-focused-on-renal-metrics-100634690","NCT07542964","Transgender Analysis of Nephrological Studies Focused on Renal Metrics","TRANSFORM","Inclusion Criteria:\n\n* Diagnosed with gender dysphoria according to DSM-V\n* Expected to start gender-affirming hormone treatment in the upcoming month\n\nExclusion Criteria:\n\n* Current or prior use of gender-affirming hormone therapy\n* Participation in other studies\n* Concomitant use of medication (specifically: antihypertensive agents, products, antidepressants, antipsychotic agents)\n* Known kidney disease (eGFR \\\u003C 60 ml\u002Fmin; UACR \\> 2.5 mg\u002Fmmol)\n* Diabetes mellitus\n* A history of cardiovascular disease (myocardial infarction; cardiac surgery or revascularization, unstable angina, heart failure, transient ischemic attack, cerebrovascular disease, or a previously undiagnosed arrhythmia)\n* Known iodine-related allergies\n* Metal in the body (such as pacemaker, ICD, neurostimulator, cochlear implant, or other metal)\n* Pregnancy\n* Claustrophobia","18 Years","40 Years",{"count":55,"type":21},60,"OBSERVATIONAL","This study investigates how sex hormones affect kidney function in people undergoing gender-affirming hormone therapy (GAHT). We know men have a faster progression of kidney disease. Earlier studies suggest that the female sex hormone estradiol may have a protective effect on kidney function while the male sex hormone testosterone may have the opposite effect. But the reasons why this happens remain unclear. By studying participants undergoing (GAHT) we gain insight into the mechanisms by which testosterone and estradiol influence the kidneys. People undergoing GAHT provide a unique chance to study how sex hormones interact with the kidneys. The results may help us to understand why men and women exhibit differences in kidney disease development. This study will include 30 men and 30 women, aged 18 to 40, who start GAHT. Participants will have three study visits, two of which will happen during their scheduled healthcare appointments. During the first visit, a screening will take place to check if patients can take part in the study. At study visits before and after one year of therapy, kidney function is measured, kidney MRI is performed, urine is collected and a small sample of fat tissue. Taking part in the study does not delay the start of GAHT.",[59,27,60],"Kidney Disease","Transgender Individuals",[62,63,64,65,66],"Transgender individuals","Kidney disease","Kidney injury","Gender affirming hormone treatment","Sex hormones","NOT_YET_RECRUITING","2026-04-17",{"date":70,"type":36},"2026-04-21",{"date":72,"type":21},"2026-09",{"date":74,"type":21},"2028-09",{"name":76,"class":43},"Amsterdam UMC, location VUmc",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":87,"conditions":88,"keywords":93,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":4},"100623204","id-entity-trial--evaluating-serial-t-id-monitoring-100623204","NCT07393594","ID-ENTITY Trial- Evaluating Serial T-ID Monitoring","A Prospective, Multicenter, Observational Study Evaluating Serial T-ID Monitoring for the Prevention of CMV Disease and BK Virus-Associated Nephropathy Following Kidney Transplantation","ID-ENTITY","Inclusion Criteria:\n\n* Participants must meet all the following criteria:\n\n  * Written informed consent and HIPAA authorization obtained prior to any study-related data collection.\n  * Age ≥18 years at the time of enrollment.\n  * Recipient of a kidney transplant, including:\n  * Primary or repeat kidney transplantation\n  * Living-donor or deceased-donor transplantation\n  * At 1 month post-kidney transplant at the time of enrollment.\n  * Receiving maintenance immunosuppressive therapy per institutional standard of care.\n  * Selected by the treating provider to undergo TRAC testing as part of usual post-transplant clinical monitoring.\n\nExclusion Criteria:\n\n* Recipient of a combined organ transplant involving a non-renal solid organ (e.g., kidney-liver, kidney-heart) and\u002For islet cell transplantation.\n* History of prior non-renal solid organ transplantation or islet cell transplantation.\n* Known pregnancy at the time of enrollment.\n* Known active viral infection at enrollment with any of the following:\n* Hepatitis B surface antigen (HBsAg)-positive\n* Hepatitis B virus (HBV) nucleic acid testing (NAT)-positive\n* Human immunodeficiency virus (HIV) infection or HIV NAT-positive\n* \\*Known active BK virus-associated nephropathy (BKVAN) or CMV disease at the time of enrollment.\n* Medical, psychiatric, or social condition that, in the opinion of the Investigator, would interfere with the participant's ability to provide informed consent or comply with study procedures.\n* Concurrent participation in another investigational biomarker study designed to evaluate clinical utility of post-transplant molecular diagnostics.\n\n  * Participants with asymptomatic or low-level viral replication detected during routine clinical monitoring are eligible, provided there is no evidence of established CMV disease or BK virus-associated nephropathy at enrollment.",{"count":86,"type":21},1000,"To evaluate the association between time-updated CMV and BK viral loads measured monthly by T-ID and the risk of CMV disease and\u002For biopsy-proven BK virus-associated nephropathy (BKVAN) during the first 12 months following kidney transplantation, accounting for the net immune environment (TTV viral load) and allograft injury (donor-derived cell-free DNA, dd-cfDNA).",[89,27,90,91,92],"Kidney Diseases","BK Virus Infection","CMV","TTV Virus",[94,95,96,97,98,99,100],"Biomarkers testing","Kidney transplant rejection","T-ID Assay","TRAC Assay cell free DNA","Biopsy","dd-cfDNA","T-ID","2026-02-20",{"date":103,"type":36},"2026-02-24",{"date":105,"type":21},"2026-03-31",{"date":107,"type":21},"2028-10-30",{"name":109,"class":110},"Transplant Genomics, Inc.","INDUSTRY",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":119,"sex":16,"minAge":120,"maxAge":52,"enrollmentInfo":121,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":123,"conditions":124,"keywords":141,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":44},"100420250","pediatric-hypertension-and-the-renin-angiotensin-system-phrase-100420250","NCT04752293","Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)","Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE): The Role of Angiotensin-(1-7) in Hypertension and Hypertension-Induced Heart and Kidney Damage","PHRASE","INCLUSION CRITERIA: HYPERTENSION COHORT\n\n* 7-18 years of age at time of enrollment\n* Confirmed new diagnosis of primary hypertension: no identifiable secondary cause, referred to hypertension or nephrology clinic\n\n  * Age \\\u003C13 years: BP ≥95th %ile or ≥130\u002F80 mmHg (whichever is lower)\n  * Age ≥13 years: BP ≥130\u002F80 mmHg\n* Participants and their caregivers must be willing and able to commit to completing the study assessments\n\nEXCLUSION CRITERIA: HYPERTENSION COHORT\n\n* \\\u003C7 years or \\>18 years of age at time of enrollment\n* BP confirmed as normal or in the elevated BP category based on ≥3 prior office BP measurements on separate days;\n\n  * Age \\\u003C13 years: BP \\\u003C95th %ile or \\\u003C130\u002F80 mmHg (whichever is lower)\n  * Age ≥13 years: BP \\\u003C130\u002F80 mmHg\n* A confirmed secondary cause of hypertension\n* Confounding medical condition (heart or kidney disease \\[except hypertension-associated heart changes on echocardiogram or albuminuria\\], vascular\u002Finflammatory disease, or diabetes)\n* Inability to complete study assessments\n* Non-English\u002FSpanish speakers\n* Current pregnancy\n* Ward of the State\n\nINCLUSION CRITERIA: CONTROL COHORT\n\n* 7-18 years of age at time of enrollment\n* Normal BP based on ≥3 prior office BP measurements on separate days;\n\n  * Age \\\u003C13 years: BP \\\u003C90th %ile or \\\u003C120\u002F80 mmHg (whichever is lower)\n  * Age ≥13 years: BP \\\u003C120\u002F80 mmHg\n* Participants and their caregivers must be willing and able to commit to completing the study assessments\n\nEXCLUSION CRITERIA: CONTROL COHORT\n\n* \\\u003C7 or \\>18 years of age at time of enrollment\n* Elevated BP or hypertension, based on ≥3 prior office BP measurements on separate days:\n\n  * Age \\\u003C13 years: BP ≥90th %ile or ≥120\u002F80 mmHg (whichever is lower)\n  * Age ≥13 years: BP ≥120\u002F80 mmHg\n* History of elevated BP or hypertension\n* Current use of BP-lowering medications\n* Confounding medical condition (heart or kidney disease, vascular\u002Finflammatory disease, or diabetes)\n* Inability to complete study assessments\n* Non-English\u002FSpanish speakers\n* Current pregnancy\n* Ward of the State",true,"7 Years",{"count":122,"type":21},125,"Studying the causal roles of components of the renin-angiotensin-aldosterone system (including angiotensin-(1-7) (Ang-(1-7)), angiotensin-converting enzyme 2 (ACE2), Ang II, and ACE), uric acid, and klotho in pediatric hypertension and related target organ injury, including in the heart, kidneys, vasculature, and brain. Recruiting children with a new hypertension diagnosis over a 2-year period from the Hypertension and Pediatric Nephrology Clinics affiliated with Brenner Children's Hospital at Atrium Health Wake Forest Baptist and Atrium Health Levine Children's Hospital. Healthy control participants will be recruited from local general primary care practices. Collecting blood and urine samples to analyze components of the renin-angiotensin-aldosterone system (Ang-(1-7), ACE2, Ang II, ACE), uric acid, and klotho, and measuring blood pressure, heart structure and function, autonomic function, vascular function, and kidney function at baseline, year 1, and year 2. Objectives are to investigate phenotypic and treatment response variability and to causally infer if Ang-(1-7), ACE2, Ang II, ACE, uric acid, and klotho contribute to target organ injury due to hypertension.",[125,126,127,128,129,89,27,130,131,132,133,134,135,136,137,138,139,140],"Hypertension","Left Ventricular Hypertrophy","Left Ventricular Dysfunction","Left Atrial Dilatation","Left Ventricular Diastolic Dysfunction","Kidney Dysfunction","Sodium Urine High","Blood Pressure Disorders","Uric Acid Retention","Angiotensin Hypertension","Autonomic Dysfunction","Autonomic Imbalance","Pediatric Kidney Disease","Pediatric Obesity","Proteinuria","Albuminuria",[142,143,125,144,145,126,140,146,147,148,149,150,151,152,153,154,155,156,157,158,129,27,159,160,138,161,162,163,164],"High Blood Pressure","Elevated Blood Pressure","Pediatric Hypertension","Target Organ Damage","Uric Acid","Klotho","Fibroblast Growth Factor 23","Renin-Angiotensin-Aldosterone System","Renin-Angiotensin System","Angiotensin-(1-7)","Angiotensin II","Angiotensin-Converting Enzyme 2","Angiotensin-Converting Enzyme","Causal Inference","Causal Mediation Analysis","Sensitivity Analysis","Predictive Analysis","Heart Rate Variability","Sodium","Lifecourse","Kidney Function","Ambulatory Blood Pressure Monitoring","Echocardiogram","2025-12-04",{"date":167,"type":36},"2025-12-11",{"date":169,"type":36},"2021-05-19",{"date":171,"type":21},"2026-12",{"name":173,"class":43},"Wake Forest University Health Sciences",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":119,"sex":16,"minAge":52,"maxAge":180,"enrollmentInfo":181,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":183,"conditions":184,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":44},"100451196","study-on-the-establishment-of-a-system-for-early-warning-and-prognostic-evaluation-of-patients-with-heat-stroke-100451196","NCT05155358","Study on the Establishment of a System for Early Warning and Prognostic Evaluation of Patients With Heat Stroke","Inclusion Criteria:\n\n1. The patient voluntarily signs an informed consent form;\n2. Adult patients who meet the criteria for heat stroke;\n3. Heat stroke is defined as heat stroke (Heat Stroke, HS) is a serious fatal disease caused by heat injury factors acting on the body, accompanied by multiple organ damage.\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years old or \\>90 years old;\n2. Patients with advanced tumors, Pregnancy or lactation;\n3. Patients who missed out during treatment and whose data are incomplete.","90 Years",{"count":182,"type":21},150,"Heat stroke is a clinical syndrome with high incidence and high fatality rate in summer. Patients with liver, kidney, and brain damage are prone to secondary MODS, and the prognosis is poor due to high medical costs. At present, there is no unified diagnostic criteria for acute liver injury associated with heat stroke, and the commonly used prognosis scores are rarely included in liver injury indicators, which is not good for practicality.",[185,186,187,188,189,27],"Heat Stroke","Early Waking","MODS","Proteinosis","Liver Injury","2025-08-10",{"date":192,"type":36},"2025-08-14",{"date":194,"type":21},"2025-08-31",{"date":196,"type":21},"2027-12-31",{"name":198,"class":43},"Xijing Hospital",{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":22,"phases":209,"briefSummary":211,"conditions":212,"keywords":216,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":230,"locationsCount":44},"100461044","intravenous-vs-oral-hydration-to-reduce-the-risk-of-post-contrast-acute-kidney-injury-after-intravenous-contrast-enhanced-computed-tomography-in-patients-with-severe-chronic-kidney-disease-100461044","NCT05283512","Intravenous vs. Oral Hydration to Reduce the Risk of Post-Contrast Acute Kidney Injury After Intravenous Contrast-Enhanced Computed Tomography in Patients With Severe Chronic Kidney Disease","Intravenous vs. Oral Hydration to Reduce the Risk of Post-Contrast Acute Kidney Injury After Intravenous Contrast-Enhanced Computed Tomography in Patients With Severe Chronic Kidney Disease (ENRICH): A Randomized Controlled Trial","ENRICH","Inclusion Criteria:\n\n* eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m2\n* Scheduled for elective IV CECT\n* Age ≥ 18\n* Signed informed consent\n\nExclusion Criteria:\n\n* Allergy to Iodine\n* Pregnancy\n* Active dialysis treatment\n* Acute infectious or inflammatory disease\n* Acute pre- and\u002For post-renal kidney failure\n* Unable to understand study information",{"count":208,"type":21},254,[210],"NA","The use of contrast media (CM) poses a risk of post-contrast acute kidney injury (PC-AKI), especially among patients chronic kidney disease (CKD). International guidelines recommend intravenous (IV) hydration with isotonic 0.9% NaCl for three-four hours pre-contrast and four-six hours post-contrast. Recent studies have proven that oral hydration or no hydration is non-inferior to IV hydration in patients with mild to moderate CKD (eGFR 30-60 mL\u002Fmin\u002F1.73 m2). However, no randomized controlled trials have evaluated alternative hydration methods against the guideline-recommended hydration protocol for the prevention of PC-AKI in high-risk patients with severe CKD (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m2).\n\nThus, the main focus of this trial is to evaluate IV hydration vs. oral hydration for their efficacy to prevent of PC-AKI in patients with severe CKD, who are scheduled for an elective contrast-enhanced CT-scan (CECT) with IV contrast-administration.\n\nOur research hypotheses consist of the following:\n\n1. Oral hydration with bottled tap water is non-inferior to IV-hydration with isotonic 0.9% NaCl as renal prophylaxis to prevent PC-AKI in patients with severe CKD referred for an elective IV CECT.\n2. NGAL and cfDNA are early and precise plasma and urinary biomarkers of PC-AKI with excellent diagnostic and prognostic accuracy for PC-AKI, dialysis, renal adverse events, hospitalization, progression in CKD-symptoms, and all-cause mortality.",[213,27,214,215],"Contrast-induced Nephropathy","Kidney Failure, Chronic","Risk Reduction",[217,218,219,220,221,222,223],"Intravenous","Contrast material","Computed Tomography","Cardiac CT","Prophylaxis","Oral Hydration","IV-hydration","2025-07-29",{"date":226,"type":36},"2025-08-01",{"date":228,"type":36},"2022-04-20",{"date":196,"type":21},{"name":231,"class":43},"Odense University Hospital",{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":119,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":240,"targetDuration":242,"studyType":56,"phases":4,"briefSummary":243,"conditions":244,"keywords":249,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":267},"100416676","kidney-injury-in-times-of-covid-19-kidcov-100416676","NCT04705766","KIDney Injury in Times of COVID-19 (KIDCOV)","The KIDCOV Study: ASSESSMENT of SARS-CoV-2 Without HOSPITALIZATION as a RISK FACTOR for ACUTE KIDNEY INJURY","KIDCOV","Inclusion Criteria:\n\n* Result of PCR-based COVID-19 test conducted in the past 4 weeks posted in EMR of participating AMC\n* Age 18 years or older at enrollment\n* Race\u002Fethnicity, sex, age, and phone and\u002For home\u002Femail address provided\n\nExclusion Criteria:\n\n* Failure of a candidate participant to give written informed consent to comply with the study protocol\n* Hospitalization up to 4 weeks after SARS-CoV-2 test\n* History of kidney transplant\n* History of dialysis",{"count":241,"type":21},2000,"1 Year","There is an unmet need to evaluate the impact of sub-clinical\u002Fmild COVID19 disease in the outpatient setting on prevalent and incident renal injury, as this data is currently unavailable. To capture the diversity of race\u002Fethnic risk and COVID19 related municipal shelter-in-place guidance, the investigators will enroll COVID19-negative and COVID19-positive samples balanced by race\u002Fethnicity from 3 different states, California, Michigan, and Illinois. Study endpoints will be assayed from urine samples mailed to the study team at 2, 6, and 12 months after their date of PCR test, with no requirement for these individuals to leave their homes to participate.",[245,246,247,248,27],"SARS-CoV Infection","Covid19","Corona Virus Infection","Acute Kidney Injury",[250,248,251,252,253,254,255,256,257,27],"SARS-CoV-2","COVID-19","Coronaviurs","COVID-19 Infection","SARS-CoV-2 infection","Coronavirus infection","COVID-19 and Acute Kidney Injury","SARS-CoV-2 & Kidney Injury Risk Factors","2025-07-24",{"date":260,"type":36},"2025-07-28",{"date":262,"type":36},"2021-03-01",{"date":264,"type":21},"2027-03",{"name":266,"class":43},"University of California, San Francisco",3,{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":274,"eligibilityCriteria":275,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":22,"phases":278,"briefSummary":280,"conditions":281,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":44},"100501707","phase-4-sgc-stimulation-perioperative-vascular-reactivity-and-organ-injury-in-cardiac-surgery-100501707","NCT05812755","SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery","The Effects of Soluble Guanylyl Cyclase Stimulation on Perioperative Vascular Reactivity and Organ Injury in Cardiac Surgery","SOLSTICE","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Elective open-heart surgery, defined as surgery on the heart or aorta that requires sternotomy or thoracotomy\n\nExclusion Criteria:\n\n1. Intolerance to vericiguat\n2. Use of other soluble guanylyl cyclase stimulators or current use of phosphodiesterase-5 inhibitors\n3. Pregnancy or breast feeding. Pregnancy will be excluded in women of child-bearing potential by a urine or serum beta hcg test\n4. Renal replacement therapy within 30 days prior to screening\n5. Estimated glomerular filtration rate \\\u003C15 ml\u002Fmin per 1.73 m2 per Chronic Kidney Disease Epidemiology collaboration (CKD-EPI) equation at time of screening\n6. Systolic blood pressure less than 120 mmHg at the time of screening\n7. Prior kidney transplantation\n8. History of significant liver dysfunction (defined as Child-Pugh class C)\n9. Surgery scheduled to be performed with circulatory arrest\n10. Surgery scheduled to correct a major congenital heart defect\n11. Extracorporeal membrane oxygenation (ECMO) prior to surgery\n12. Active systemic infection or surgery for infectious endocarditis\n13. Ventricular assist device or intraaortic balloon pump support prior to surgery\n14. Prisoners",{"count":277,"type":21},170,[279],"PHASE4","The goal of this mechanistic clinical trial is to learn about the effects of medications called soluble guanylyl cyclase stimulators on vascular function and markers of kidney and brain injury in patients having heart surgery. The main questions it aims to answer are:\n\n1. Does soluble guanylyl cyclase stimulation improve blood vessel function compared to placebo?\n2. Does soluble guanylyl cyclase stimulation decrease markers of kidney injury and brain injury compared to placebo?\n\nParticipants will be randomized to a soluble guanylyl cyclase stimulator called vericiguat or placebo, and researchers will compare vascular function and markers of brain and kidney injury to see if vericiguat improves vascular function and reduces markers of injury.\n\nThis will provide important information to determine the underlying reasons that patients have some kidney and brain function problems after having heart surgery.",[282,283,27,284,285],"Endothelial Dysfunction","Vascular Diseases","Brain Disease","Vascular Inflammation","2025-07-02",{"date":288,"type":36},"2025-07-08",{"date":290,"type":36},"2023-05-19",{"date":292,"type":21},"2027-11",{"name":294,"class":43},"Vanderbilt University Medical Center",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":302,"enrollmentInfo":303,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":305,"conditions":306,"keywords":308,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":318,"leadSponsor":320,"locationsCount":322},"100431802","immune-checkpoint-inhibitors-nephrotoxicity-100431802","NCT04902846","Immune Checkpoint Inhibitors Nephrotoxicity","Application of Biomarkers of Renal Damage in Patients Treated With Immune Checkpoint Inhibitors","Inclusion Criteria:\n\n* Patients waiting for immunotherapy or combination immunotherapy \u002F platinum compounds\n\nExclusion Criteria:\n\n* Patients who are terminally ill\n* Patients who do not wish to sign the informed consent","100 Years",{"count":304,"type":21},220,"In recent years, immunotherapy has been postulated as one of the most effective strategy in the fight against cancer. The greatest success in this field has been achieved through the inhibition of molecules involved in the brake of the adaptive immune response. The compounds capable of blocking the action of these molecules constitute the \"immune checkpoint inhibitors\" (ICI). Despite its efficacy, the treatment with ICI causes adverse effects, and in the case of kidney damage, the prognosis has been shown to worsen in cancer patients who develop renal dysfunction. Currently, the diagnosis based on laboratory tests is insufficient to predict the underlying kidney injury and identify the type of damage. The hypothesis proposed that the renal lesion could be subclinical, and therefore the possibility of using new urinary biomarkers could be a useful diagnostic tool that would allow these patients to be managed in a preventive (risk markers) and early way (early markers), and even to elucidate if renal damage is due to this therapy or to other factors (differential diagnostic markers). To develop this hypothesis it is proposed to validate biomarkers in patients treated with ICI by developing a prospective study. The diagnostic products derived from this study will improve the clinical practice of cancer treatment with ICI, and therefore the expectancy and quality of life of patients.",[27,307],"Antineoplastics Toxicity",[309,310,311,312,313],"Diagnosis","Nephrotoxicity","Prevention","Oncology","Immune check point inhibitors","2025-02-25",{"date":316,"type":36},"2025-02-26",{"date":169,"type":36},{"date":319,"type":21},"2030-12-30",{"name":321,"class":43},"R. Laura Vicente Vicente",2,{"id":324,"slug":325,"hasResults":11,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":330,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":332,"conditions":333,"keywords":334,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":44},"100576144","evaluation-of-urinary-biomarkers-trend-in-preterm-very-low-birth-weight-infants-100576144","NCT06781476","Evaluation of Urinary Biomarkers Trend in Preterm Very Low Birth Weight Infants","Evaluation of Urinary Biomarkers Trend in Preterm Very Low Birth Weight Infants: Influence of Clinical and Therapeutic Factors","Inclusion Criteria:\n\n* Gestational age \\\u003C32 weeks or birth weight \\\u003C1500 g;\n* Admission at birth to the Neonatal Intensive Care Unit of the IRCCS A.O.U. of Bologna Policlinico di S. Orsola;\n* Obtaining informed consent from parents\u002Flegal representatives.\n\nExclusion Criteria:\n\n* malformations of the urinary system;\n* major congenital anomalies, including congenital heart disease;\n* syndromic picture or known genetic abnormalities;\n* perinatal asphyxia (defined by the finding on arterial blood gas from cord blood of pH≤7.0 or base excess ≤-12 mMol\u002FL and\u002For Apgar ≤5 or need for resuscitation at 10' of life);\n* infants who died in the first 48 hours of life or underwent major surgery during the study period.",{"count":331,"type":21},78,"The purpose of this study is to define the temporal patterns of urinary biomarkers (CysC, EGF, KIM-1, NGAL, β2-Microglobulin, OPN, and MOD) in the first two weeks of life in preterm and\u002For very low birth weight (VLBW) infants in relation to the effect of specific factors (hsPDA, prenatal Doppler alterations) and drug therapies. Another objective is then to evaluate the predictivity of these biomarkers with respect to the occurrence of renal damage in preterm infants and possible cut-off values",[27],[335,336,337],"kidney injury","urinary biomarkers","premature newborns","2025-01-13",{"date":340,"type":36},"2025-01-17",{"date":342,"type":36},"2022-12-07",{"date":344,"type":21},"2025-06-15",{"name":346,"class":43},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":348,"slug":349,"hasResults":11,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":353,"eligibilityCriteria":354,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":22,"phases":357,"briefSummary":358,"conditions":359,"keywords":362,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":322},"100571742","preventing-delayed-graft-function-in-kidney-transplant-patients-100571742","NCT06724211","Preventing Delayed Graft Function in Kidney Transplant Patients","Preventing Delayed Graft Function in Kidney Transplant Patients: A Single-centre, Randomised, Feasibility Trial","PDF","Inclusion Criteria:\n\n* ≥ 18 years\n* Patients undergoing kidney transplantation\n* Living and deceased donor recipients\n\nExclusion Criteria:\n\n* Multi-organ transplant\n* Pre-emptive KT\n* Arterial line not planned for surgery",{"count":356,"type":21},50,[210],"The health and quality of life benefits of kidney transplantation are reduced by delayed graft function (DGF). There are a number of modifiable risk factors associated with DGF, such as intraoperative hypotension, the type of intravenous fluid used, glycemic control, and the restriction of blood transfusions. However, these factors have been assessed individually, and their collective effect on reducing the risk of DGF requires further investigation. We first propose a pilot RCT to establish the feasibility of a definitive RCT examining the impact of a treatment bundle of care on DGF.\n\nThis will be a single centre, double-blinded pilot RCT including 50 adults undergoing kidney transplantation. Patients will be randomized to either the experimental group, which will consist of a treatment bundle of care, or to the control group, which will consist of routine clinical care for kidney transplant patients. The treatment bundle of care will consist of: the use of plasmalyte for fluid management, maintaining mean arterial pressure \\> 75 mmHg, identify and treat blood glucose \\> 9 mmol\u002FL, and a restrictive criteria for red blood cell transfusions (i.e. hemoglobin (Hb) \\\u003C 70 g\u002FL).\n\nThe primary outcome of this pilot study is the recruitment rate. Recruitment rate will be defined as the number of patients who are approached to participate in the study and who are randomized to either the experimental or control group, as a percentage of the total number of eligible kidney transplant patients. The secondary outcomes are: 1) protocol adherence rate and 2) follow-up rate. Protocol success will be defined as a ≥90% compliance with at least 3 of the 4 treatment bundle components. Patient follow-up will end at 90-days after transplant and the target is to follow ≥90% of the patients until this time. DGF and acute rejection will not be assessed in the feasibility trial, and instead this data will be analyzed in the full trial.",[360,361,27],"Kidney Transplant","Kidney Failure",[360,363],"Surgical Bundle","2024-12-05",{"date":366,"type":36},"2024-12-09",{"date":368,"type":21},"2025-01-15",{"date":370,"type":21},"2026-04",{"name":372,"class":43},"University Health Network, Toronto",{"id":374,"slug":375,"hasResults":11,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":379,"eligibilityCriteria":380,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":383,"conditions":384,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":393,"locationsCount":44},"100561097","association-between-venous-excess-ultrasound-grading-system-and-acute-kidney-injury-in-the-icu-population-100561097","NCT06585722","Association Between Venous Excess Ultrasound Grading System and Acute Kidney Injury in the ICU Population","The Association Between Venous Excess Ultrasound, the Lung Ultrasound Score and Acute Kidney Injury and Death in the Intensive Care Unit Population","VExUS ICU","Inclusion Criteria:\n\n* all patients admitted to the ICU 18 years or older expected to stay in the ICU for more than 24 hours\n\nExclusion Criteria:\n\n* any obstruction between the righ atrium and structures assessed by VExUS\n* a medical history of: Major cardiac shunts (e.g. atrial septum defect), Tricuspid regurgitation, dialysis, portal hypertension, pulmonary hypertension, interstitial lung disease, recipients of a kidney of liver transplant.\n* patients in whom an ultrasound assesment is unfeasible e.g. a BMI over 40",{"count":382,"type":21},136,"Fluid resuscitation is one of the cornerstones of treatment in ICU patients. Nonetheless, excessive fluid administration can lead to fluid overload which has been associated with worse outcomes in the ICU. To prevent this, assessments of fluid responsiveness are commonly employed. However, fluid responsiveness does not take fluid tolerance into account. Fluid tolerance is the idea that a patient might still be fluid responsive but might already be at risk of the detrimental effects of fluid therapy. Recent developments in point of care ultrasound e.g. the Venous excess ultrasound might help identify patients at risk of fluid overload. However its association with patient relevant outcomes in the ICU remains unclear.",[385,27,386],"Fluid Overload","Make-30","2024-09-04",{"date":389,"type":36},"2024-09-05",{"date":391,"type":36},"2023-02-01",{"date":389,"type":21},{"name":394,"class":43},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":396,"slug":397,"hasResults":11,"nctId":398,"briefTitle":399,"officialTitle":399,"acronym":400,"eligibilityCriteria":401,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":402,"enrollmentInfo":403,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":404,"conditions":405,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":4},"100535657","western-sydney-kidney-injury-biopsy-study-100535657","NCT06254677","Western Sydney Kidney Injury Biopsy Study","WESTKiD","Inclusion Criteria:\n\n1. Had a kidney biopsy (native kidney or transplant kidney included) after year 2000\n2. Kidney biopsy sample sent to Westmead Hospital for clinical interpretation\n\nExclusion Criteria:\n\n1. Patients who have never had a kidney biopsy performed\n2. Biopsy sample not available at Westmead Hospital\n3. No information on kidney function (serum creatinine or eGFR)","80 Years",{"count":86,"type":21},"The investigators aim to develop a clinically validated, histological acute tubular injury (ATI) scoring system to help improve diagnostic precision and predict clinical outcomes following ATI.\n\nTo use an unbiased, data-driven approach, correlating pathological features (including digital pathology), key signatures using spatial technologies (transcriptomics or proteinomics) with relevant clinical outcomes. Spatial technologies (including spatial transcriptomics and spatial proteinomics) allow the use of 'precision pathology' to study the critical link between molecular characteristics to histological structure.",[27],"2024-04-22",{"date":408,"type":36},"2024-04-24",{"date":410,"type":21},"2024-05-01",{"date":412,"type":21},"2040-01-01",{"name":414,"class":43},"Western Sydney Local Health District",{"id":416,"slug":417,"hasResults":11,"nctId":418,"briefTitle":419,"officialTitle":419,"acronym":420,"eligibilityCriteria":421,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":422,"targetDuration":242,"studyType":56,"phases":4,"briefSummary":424,"conditions":425,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":431,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":44},"100464701","perioperative-longitudinal-study-of-complications-and-long-term-outcomes-100464701","NCT05331118","Perioperative Longitudinal Study of Complications and Long-term Outcomes","PLUTO","Inclusion Criteria:\n\n\\- Undergoing an elective, high-risk gastro-intestinal or vascular procedure, or intermediate risk procedure (including gynaecological, orthopaedic and head and neck surgery) if the procedure includes a laparotomy and\u002For is associated with a scheduled hospital length of stay ≥ 5 days.\n\nExclusion Criteria:\n\n* \\\u003C 18 years of age\n* Emergency surgery\n* Severe anaemia (Hb \\\u003C 4.5 mmol\u002FL)\n* Unable to provide informed consent",{"count":423,"type":21},9000,"Purpose: with an increased risk of complications. Improved preoperative risk stratification and earlier diagnosis of these complications may ameliorate postoperative recovery and improve long-term outcomes. The perioperative longitudinal study of complications and long-term outcomes (PLUTO) aims to establish a comprehensive biorepository that will facilitate research in this field.\n\nPatients undergoing elective intermediate to high-risk non-cardiac surgery are eligible for enrolment. For the first 7 postoperative days (or longer as indicated), participants will be subjected to daily bedside visits by dedicated observers, who adjudicate clinical events and perform non-invasive physiological measurements (including handheld spirometry and single-channel EEG). In addition, we will collect blood samples as well as microbiome specimens at selected time points. Primary study outcomes are the postoperative occurrence of nosocomial infections, major adverse cardiac events, pulmonary complications, acute kidney injury and delirium. Secondary outcomes include mortality as well as long-term psychopathology, cognitive dysfunction, and quality of life.\n\nPLUTO is the first perioperative biobank worldwide that includes a broad range of high-risk surgical patients, collecting prospective bedside data as well as both blood and microbiome specimens during the entire perioperative period. The data and materials collected in PLUTO will be used to develop, externally validate, and update prognostic prediction models for improved risk assessment, to test novel biomarkers for early detection of postoperative complications and to study the aetiology, attributable morbidity and mortality related to these events.",[426,427,428,27,429],"Perioperative Complication","Infections","Myocardium; Injury","Delirium","2023-11-28",{"date":432,"type":36},"2023-11-29",{"date":434,"type":36},"2020-02-21",{"date":436,"type":21},"2040-02-21",{"name":438,"class":43},"UMC Utrecht",{"id":440,"slug":441,"hasResults":11,"nctId":442,"briefTitle":443,"officialTitle":443,"acronym":444,"eligibilityCriteria":445,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":446,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":448,"conditions":449,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":44},"100469790","research-on-optimal-diagnosis-and-treatment-of-cardiorenal-syndrome-100469790","NCT05397392","Research on Optimal Diagnosis and Treatment of Cardiorenal Syndrome","ODT-CRS","Inclusion Criteria:\n\nPatients meet the diagnosis of various types of cardiorenal syndrome according to the classification standards of various types formulated by KDIGO and ADQI expert consensus. Different syndromes were identified and classified into five subtypes. Acute CRS (type 1): acute worsening of heart function (AHF-ACS) leading to kidney injury and\u002For dysfunction. Chronic cardio-renal syndrome (type 2): chronic abnormalities in heart function (CHF-CHD) leading to kidney injury and\u002For dysfunction. Acute reno-cardiac syndrome (type 3): acute worsening of kidney function (AKI) leading to heart injury and\u002For dysfunction. Chronic reno-cardiac syndrome (type 4): chronic kidney disease leading to heart injury, disease, and\u002For dysfunction. Secondary CRS (type 5): systemic conditions leading to simultaneous injury and\u002For dysfunction of heart and kidney.\n\nExclusion Criteria:\n\nPregnant or breastfeeding women; Female patients with recent birth plans; Patients who cannot follow up on medications.",{"count":447,"type":21},1200,"To estimate the characteristics, pathogenesis, risk factors and intervention measures for different stages of heart and kidney diseases, and to optimize the curative effects of different treatment schemes",[450,89,27,451,452,453],"Heart Failure","Heart Valve Diseases","Dialysis; Complications","Coronary Heart Disease","2022-05-30",{"date":456,"type":36},"2022-06-02",{"date":458,"type":36},"2016-01",{"date":460,"type":21},"2027-12",{"name":462,"class":43},"Nanjing First Hospital, Nanjing Medical University"]